Cargando…

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

BACKGROUND: For women with ductal carcinoma in situ (DCIS) of the breast, the risk of developing an ipsilateral breast event (IBE; defined as local recurrence of DCIS or invasive carcinoma) after surgical excision without radiation is not well defined by clinical and pathologic characteristics. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Solin, Lawrence J., Gray, Robert, Baehner, Frederick L., Butler, Steven M., Hughes, Lorie L., Yoshizawa, Carl, Cherbavaz, Diana B., Shak, Steven, Page, David L., Sledge, George W., Davidson, Nancy E., Ingle, James N., Perez, Edith A., Wood, William C., Sparano, Joseph A., Badve, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653823/ https://www.ncbi.nlm.nih.gov/pubmed/23641039 http://dx.doi.org/10.1093/jnci/djt067

Ejemplares similares

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831
por: Perez, Edith A., et al.
Publicado: (2015)

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018)

Is conservative management of ductal carcinoma in situ risky?
por: Zheng, Lan, et al.
Publicado: (2022)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

Single cell heterogeneity in ductal carcinoma in situ of breast
por: Gerdes, Michael J, et al.
Publicado: (2017)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast
por: Badve, Sunil S., et al.
Publicado: (2021)

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
por: Li, Haojia, et al.
Publicado: (2019)

Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast
por: Badve, Sunil S., et al.
Publicado: (2022)

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
por: Baehner, FL, et al.
Publicado: (2009)

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone
por: Rakovitch, Eileen, et al.
Publicado: (2015)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
por: Sparano, Joseph A., et al.
Publicado: (2021)

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

Ductal Carcinoma In Situ of the Breast
por: Lee, Richard J., et al.
Publicado: (2012)

Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model
por: Ghose, Soumya, et al.
Publicado: (2023)

Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis
por: Gorringe, Kylie L., et al.
Publicado: (2017)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Modeling Human Ductal Carcinoma In Situ in the Mouse
por: Behbod, Fariba, et al.
Publicado: (2018)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Immunohistochemical categorisation of ductal carcinoma in situ of the breast
por: Meijnen, P, et al.
Publicado: (2008)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Ductal carcinoma in situ (DCIS)
por: Holland, R
Publicado: (2002)

Breast Ductal Carcinoma In Situ
por: Sacchini, Virgilio, et al.
Publicado: (2012)

Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy
por: Giannakeas, Vasily, et al.
Publicado: (2018)

Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer
por: Giannakeas, Vasily, et al.
Publicado: (2020)

A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay
por: Lei, Rachel Y., et al.
Publicado: (2020)

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel
por: Malvi, Deborah, et al.
Publicado: (2022)

Mouse intraductal modeling of primary ductal carcinoma in situ
por: Hutten, Stefan J., et al.
Publicado: (2023)

Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer
por: Wei, Zhang, et al.
Publicado: (2012)

Classification of ductal carcinoma in situ by gene expression profiling
por: Hannemann, Juliane, et al.
Publicado: (2006)

Imaging of Noncalcified Ductal Carcinoma In Situ
por: Bragg, Ashley, et al.
Publicado: (2021)

Genetic predisposition to ductal carcinoma in situ of the breast
por: Petridis, Christos, et al.
Publicado: (2016)

Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer
por: Kim, Shinn Young, et al.
Publicado: (2015)

Comparison of breast ductal carcinoma in situ and ductal carcinoma in situ with microinvasion, and analysis of axillary lymph node metastasis
por: Zhang, Geng, et al.
Publicado: (2020)

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance
por: Suarez, Christopher D., et al.
Publicado: (2017)

Generation of Coronavirus-based multigene RNA vectors
por: Makia, D., et al.
Publicado: (2006)

Coronary Calcium Scanning in Patients after Adjuvant Radiation for Early Breast Cancer and Ductal Carcinoma In situ
por: Chang, Monique, et al.
Publicado: (2013)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Disentangling the multigenic and pleiotropic nature of molecular function
por: Stoney, Ruth A, et al.
Publicado: (2015)

The P450 multigene family of Fontainea and insights into diterpenoid synthesis
por: Mitu, Shahida A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oknamlibfkb7mtdht3r49qcjee